Subscriber Content Read Preview
Sanofi-Aventis reported a 64% drop in fourth-quarter net profit due largely to restructuring costs, and said talks with takeover target Genzyme are continuing, furthering months of suspense surrounding the deal.
Subscriber Content Read Preview
Orexigen said it will cut 23 jobs, resulting in a 40% reduction of its work force, after a recent regulatory rejection of its obesity drug.
Subscriber Content Read Preview
World Heart paused enrollment in a study of its Levacor heart pump, pending regulatory approval of refinements to the device.
Subscriber Content Read Preview
Elliott Advisers believes Actelion could be an attractive target for big pharma groups. But a standalone Actelion could be worth far more.
Federal officials questioned companies that make six cancer drugs about their failure to complete follow-up studies they promised to conduct in exchange for accelerated approval.
Subscriber Content Read Preview
Subscriber Content Read Preview
Subscriber Content Read Preview
Subscriber Content Read Preview
View an interactive map that shows you how stocks in the Pharmaceuticals & Biotech sector are doing today, at a glance.
Get in-depth research on Pharmaceuticals & Biotech companies, including complete news and financials, earnings estimates and more.
Ask a question about anything you choose, and let readers from the Journal Community answer it.
Hello
Your question to the Journal Community Your comments on articles will show your real name and not a username.Why?
Create a Journal Community profile to avoid this message in the future. (As a member you agree to use your real name when participating in the Journal Community)